Notes

A fund manager's notes were compiled on 2026-09-14T09:01:21.059568+00:00. The fund is called Catalyst Research, and it has a size of 0. The notes include compact receipts and originate from the PRE91108 archive. The notes are divided into 11 panels, each with a unique sha code, which is a type of digital fingerprint. The panels contain previews of various events and announcements, including SEC filings for HITI and BFRI, earnings reports for Dave & Buster's Entertainment, Inc., and conferences for EGTX. One panel mentions a suspension being lifted by the ITC, which stands for International Trade Commission, on September 1, 2026. The notes also mention specific dates and times, such as September 10, 06:00 UTC, and September 15, 12:30. The previews are not guaranteed to be up-to-date or accurate, and the originals should be read before taking any action.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. As of September 14, 2026, at 08:31:03 UTC, the fund has noted the following: IONS filed a report with the Securities and Exchange Commission (SEC) on September 4, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/874015/000114036126035802/ef20081690_8k.htm. MIRM filed a report with the SEC on September 8, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm. GIS filed a report with the SEC on July 1, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/40704/000162828026046337/gis-20260701.htm. EAT filed a report with the SEC on August 12, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/703351/000070335126000026/eat-20260810.htm. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which can be reviewed. The fund is waiting for GIS's earnings report on September 23, 2026, at 13:00 UTC, and will review the Q&A session. If GIS's organic cash is strong, the fund will record and validate the results, but if it is weak or absent, the fund will reverify the cash. The fund will not automatically enter a trade and will only review the results on the specified dates. The baseline for GIS's fiscal year 2027 is an EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%, with savings of $750 million. The fund has a frozen paper window from September 16 to September 21 and will review the results on September 23, 2026. EAT will have an investor day on September 17, 2026, from 08:30 to 11:15 CT, and the fund will review the results at 16:30 UTC. EAT will also have an earnings call on October 28, 2026, and the fund will review the results at 16:30 UTC. The fund will verify the full pipelines and early news for all stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 14, 2026, at 08:31:02 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and that reviews will be done at 12:30 UTC on September 9 for new morning results, September 10 for LOVE, and September 24 for SFIX after the September 23 AMC. The GRAL panel on September 23 is not for approval. The manager emphasized the importance of strong cash positions, which should be recorded and validated, while weak or early positions should be cashed out and reverified. No automatic orders were placed.

A fund, named catalyst research, has no size and is for research only. It started from the PRE91108 archive. On 2026-09-14 at 07:31:13, a news scan found the headline 'Tamboran Delivers First Gas Sales From the Beetaloo Basin' from TBN news. Another scan found information about CNXC, including a filing date of 2026-08-14 and a form called SCHEDULE 13G, which is a type of report filed with the Securities and Exchange Commission. A corporate calendar from TBN was also found. Additionally, a blog post from NEOV about home battery safety was discovered on 2026-09-09. Scholar Rock announced FDA approval of a drug called ISEMBYLD on 2026-09-11. A decision was made to exit a call for NEOV on September 22 and another decision for TBN on September 25. This information comes from seven panels, each with a unique identifier called a sha, which is a type of digital fingerprint.

The Catalyst research fund has a size of 0 as of September 14, 2026, at 07:01:13 UTC. Recent news includes TLX on September 13, 2026, about FDA approval of a brain cancer imaging drug, and AVO, ABM, and ROIV on September 8, 2026, about financial results and study outcomes. There are also SEC filings from UNFI on September 8, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 9, 2026. Additionally, EPM declared a cash dividend on September 10, 2026, and IPHA filed a report on the same day. Website checks resulted in HTTP200 responses with specific hashes for KGF, ASKUL, IPHAnews, and SOBI. The research concludes with a reminder to read originals and validate strong or new information, and to cash out and reverify weak or absent information. There are conditional plans for IPHA on September 17 and Sobi receipt in Q1 2028. Certain monitors are preserved, and sources and dates are recorded in the job script and journal. No orders have been placed.

A fund manager reviewed six items. The fund is called Catalyst Research Only and it has a size of 0. The information comes from the PRE91108 archive, which was accessed on 2026-09-14 at 05:31:05.969408+00:00. The items include a news headline from TBNnews about Tamboran delivering first gas sales, a filing from CNXC, a corporate calendar from Tamboran, an announcement from Scholar Rock about FDA approval, a blog post from Neovolta about home battery safety, and a list of groups including SRRK, SCHL, and PRAX, with instructions to exit certain positions on specific dates.

The Catalyst fund is for research only on IONS, MIRM, GIS, and EAT, with no current size. As of September 14, 2026, at 04:16:03 UTC, the fund has the following notes: IONS filed with the SEC on September 4, 2026, MIRM filed on September 8, 2026, GIS filed on July 1, 2026, and EAT filed on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, and will have earnings on September 23, 2026. The fund will review GIS's organic cash and guidance, and will not automatically enter a trade. The baseline for GIS is an EPS of $3.00-3.20 and organic growth of -1.5% to +0.5%. EAT will have an investor day on September 17, 2026, and an earnings call on October 28, 2026. The fund will review EAT's organic cash and will not automatically trade. The fund has four SEC filings, one discovery, and two reviews for GIS and EAT. The fund is for research only and has no orders as of September 14, 2026, at 04:16:07 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 14, 2026, at 04:16:02 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The fund also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 and 10, and SFIX results on September 24 after the market closes on September 23. The GRAL panel meeting is not for approval. The fund has a strong cash position, which will be validated, while weak or early positions will be verified. No automatic orders were placed.

A fund manager reviewed notes from the Catalyst research fund, which has a size of 0 and compact receipts originating from the PRE91108 archive, as of 2026-09-14T03:16:09.925795+00:00. The manager looked at six panels of information. The first panel had 71 characters and a unique identifier, or sha, of 0060a4f6d2da48b1. The second panel had 736 characters and mentioned TBN news from September 8, 2026, about Tamboran delivering first gas sales from the Beetaloo Basin, which is a gas field. The third panel had 483 characters and mentioned a company called CNXC, which filed a SCHEDULE 13G form on August 14, 2026, a type of filing that means a company is reporting its ownership stake in another company. The fourth panel had 416 characters and mentioned an event on Tamboran's corporate calendar. The fifth panel had 1708 characters and mentioned Scholar Rock announcing FDA approval of a drug called ISEMBYLD on September 11, 2026. The sixth panel had 2979 characters and mentioned a company called NEOV, which posted about home battery safety on September 9, 2026. The seventh and final panel mentioned a group of companies, including SRRK, SCHL, and PRAX, and noted that the fund would exit its position in NEOV on September 22 and TBN on September 25.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-14T02:46:04.642108+00:00 UTC. There are several news updates: TLX on Sunday, September 13, 2026, about the FDA approving Telix's brain cancer imaging drug Pixclara, AVO on Tuesday, September 8, 2026, about Mission Produce's fiscal 2026 third quarter financial results, ABM on Tuesday, September 8, 2026, about ABM's fiscal third quarter 2026 results, and ROIV on Tuesday, September 8, 2026, about Roivant's positive results from the Phocus study of mosliciguat. There are also several financial filings: UNFI's 8-K filing on September 8, 2026, DRI's 10-K filing on July 24, 2026, PPIH's 10-Q filing on September 9, 2026, MRK's 10-Q filing on August 7, 2026, and WLTH's 8-K filing on September 9, 2026. Additionally, there are updates from EPM on Thursday, September 10, 2026, about declaring a $0.12 per share cash dividend, and IPHA's 6-K filing on September 10, 2026. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI all returned a status code of 200 with hashes dda88bf6ef8ad805, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research is ongoing and no orders have been placed. The monitors for 165, 168, 167, 137, and 22 will be preserved. The sources and dates are available in the job script and journal. A decision has been made to read the originals and validate the information for strong and new updates, and to cash and reverify for weak, absent, or error updates. There is a conditional receipt for Sobi and a Q1 2028 condition for IPHA on September 17.

A fund manager for the Catalyst research fund made some notes. The fund has a size of 0 and is for research only. The notes were made on 2026-09-14 at 01:16:09.078796+00:00. The manager looked at six main points. A news scan found the headline 'Tamboran Delivers First Gas Sales From the Beetaloo Basin' from TBN news on September 8, 2026. The manager also saw a filing from CNXC on August 14, 2026, which is a type of report called a SCHEDULE 13G. Another point was about an event on the corporate calendar of Tamboran. The manager also looked at information from NEOV on September 9, 2026, about home battery safety. Additionally, the manager saw an announcement from Scholar Rock on September 11, 2026, about FDA approval of a drug called ISEMBYLD. The manager made decisions about stocks, including SRRK, NEOV, and TBN, with specific exit dates and times, such as exiting NEOV on September 22 and TBN on September 25.

The fund is called Catalyst Research and it has a size of 0. The receipts are compact and the origins are in the PRE91108 archive. The information was last updated on 2026-09-14 at 01:01:22.481370+00:00. There are 11 panels of information, including SEC filings for HITI on 2026-08-31 and BFRI on 2026-08-13. Other panels mention Dave & Buster's Entertainment, Inc., TSM, and EGTX. The panels also include information about conferences, reviews, and an ITC lifted suspension for BFRI on Sep1. The originals should be read before taking any action.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with a size of 0. The fund's status was updated on September 14, 2026, at 00:15:59 UTC. The fund manager has been reviewing SEC filings for these companies, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. A discovery was made on September 9, where Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, and its earnings will be released on September 23, with a Q&A session at 13:00 UTC. The fund manager will review the earnings and verify the cash flow, with no automatic entry into the market. The baseline EPS for GIS is $3.00-3.20, with organic growth expected to be between -1.5% and +0.5%. EAT will have an investor day on September 17 and an earnings call on October 28, with the fund manager reviewing the results and verifying the first news release. The fund manager will also review the pipelines and early news for these companies, with no automatic trades. The fund's status was updated again on September 14, 2026, at 00:16:03 UTC, with the note that it is for research only and no orders have been placed.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 14, 2026, at 00:15:59 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The fund also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 and 10, and SFIX results on September 24. The GRAL panel meeting on September 23 is not for approval. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed out and reverified. No automatic orders were placed.

A news scan found the headline from TBN news on Tuesday, September 8, 2026, stating that Tamboran delivered first gas sales from the Beetaloo Basin. A fund, named Catalyst Research, has a size of 0 and is for research only. It has compact receipts and origins in the PRE91108 archive, with a timestamp of 2026-09-13T23:16:05.961753+00:00. The fund has six names, which include TBN, CNXC, NEOV, SRRK, SCHL, and PRAX. A security filing, known as a SCHEDULE 13G, was made by CNXC on August 14, 2026. NEOV posted a blog on September 9, 2026, about home battery safety. TBN has a corporate calendar with a US Australian event in February. Scholar Rock announced FDA approval of ISEMBYLD on September 11, 2026. The fund made decisions to exit SRRK/SCHL/PRAX on September 22 and NEOV on September 23. The fund also has information on TBN for September 25.

The Catalyst research fund has a size of 0 as of September 13, 2026, at 22:46:00 UTC. Recent news includes: TLX on September 13, 2026, with FDA approval of a brain cancer imaging drug, AVO and ABM on September 8, 2026, with fiscal third-quarter financial results, and ROIV on September 8, 2026, with positive results from a study. There are also SEC filings from UNFI on September 8, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 9, 2026. Additionally, EPM declared a cash dividend on September 10, 2026, and IPHA filed a report on the same day. Website checks resulted in HTTP200 responses with hashes for KGF, ASKUL, and SOBI, but an error occurred for IPHA news. The research is for informational purposes only, with a reminder to read originals and validate strong or new information, and to revert to cash and reverify weak or absent information. There are pending events for IPHA on September 17 and Sobi with a conditional receipt for Q1 2028. Monitors 165, 168, 167, 137, and 22 are preserved, with sources and dates available in the job script and journal, and no orders have been placed.

A fund manager reviewed six names for primary receipts, replacing 205 with an exit code of 0. The fund is called Catalyst Research and its size is 0. The information comes from the PRE91108 archive and was last updated on 2026-09-13T21:01:05.475223+00:00. The review includes panels with information about various companies, including CNXC, which filed a SCHEDULE 13G form on 2026-08-14, and TBN, which delivered its first gas sales from the Beetaloo Basin. Other companies mentioned include SRRK, which announced FDA approval of a product, and NEOV, which published a blog post about home battery safety. The review also mentions a trading decision to exit a call option for NEOV on September 22 and another decision related to TBN on September 25. The originals of the panels should be read before taking any action.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with a size of 0. The fund's status was updated on September 13, 2026, at 20:01:28 UTC. The fund manager has reviewed the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund manager will review the replay. GIS is expected to release its earnings on September 23, 2026, at 13:00 UTC, with a Q&A session, but the exact time of the first release is unknown. The fund manager will review the earnings and verify the cash flow and guidance. If the cash flow is stronger, the fund manager will record and validate the results. If the cash flow is weaker or absent, the fund manager will reverify the cash flow. The fund manager has set a baseline for GIS's FY27 EPS at $3.00-3.20, with an organic growth rate of -1.5% to +0.5% and savings of $750 million. The fund manager has also reviewed EAT's investor day on September 17, 2026, and its earnings call on October 28, 2026. The fund manager will review the earnings and verify the cash flow and guidance. If the cash flow is stronger, the fund manager will record and validate the results. If the cash flow is weaker or absent, the fund manager will reverify the cash flow. The fund manager has set a frozen holdout of -19.2065% for EAT. The fund manager will verify the full pipelines and early news for all four companies.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 13, 2026, at 20:01:23 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 and 10, and SFIX results on September 24. The GRAL meeting on September 23 is not for approval. The fund has a strong cash position and will validate records, but weak or early results will require reverification. No automatic orders were placed.

A fund manager reviewed notes from the Catalyst research fund, which has a size of 0 and compact receipts. The notes originated from the PRE91108 archive and were last updated on 2026-09-13T18:46:03.062175+00:00. The manager reviewed six panels of information, including a news scan that found the headline 'Tamboran Delivers First Gas Sales From the Beetaloo Basin' from TBNnews on September 8, 2026, and a Securities and Exchange Commission filing from CNXC on August 14, 2026. The manager also reviewed information about Neovita, including a blog post on home battery safety from September 9, 2026, and an announcement from Scholar Rock about FDA approval of ISEMBYLD on September 11, 2026. The manager made decisions about stocks, including SRRK, NEOV, and TBN, and planned to exit some positions on September 22 and 25. The notes included a hash, or digital fingerprint, to verify their authenticity.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-13T18:31:06.395377+00:00. There are several news updates from various companies, including Telix Pharma on September 10, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, Roivant on September 8, 2026, UNFI on September 8, 2026, Darden Restaurants on July 24, 2026, Perma-Pipe International on September 9, 2026, Merck on August 7, 2026, and Wealthth on September 9, 2026. Additionally, there are updates from Evolution Petroleum on September 10, 2026, and Innate Pharma on September 10, 2026. The HTTP status codes for KGF, ASKUL, and SOBI are 200, with hashes dda88bf6ef8ad805, e6f0d85c03a37ce6, and d719eca30b8a5a99, respectively. However, there was an error with IPHA news due to a ValueError. The decision is to read the originals and validate the strong and new information, and to cash and reverify the weak, absent, or error information. There is a conditional receipt for Sobi and a Q1 2028 condition. The monitors 165, 168, 167, and 137, and 22 will be preserved. The sources and dates are in the job script and journal. There are no orders.

The fund is called Catalyst Research and it has a size of 0. It is compacting receipts and the origins are in the PRE91108 archive. This was done on 2026-09-13 at 17:01:13.384960+00:00. There are 11 panels of information. The first panel has 70 characters and a sha of 2fc3ed94416e8faa. The second panel has 101 characters and a sha of ec6b948aefbbcda8, and it mentions HITI SEC on 2026-08-31. The third panel has 98 characters and a sha of f66f74b11be96ebf, and it mentions BFRI SEC on 2026-08-13. The fourth panel has 215 characters and a sha of 3c5c2ff2bea8b9d1, and it mentions Dave & Buster’s Entertainment, Inc. on September 1, 2026. The fifth panel has 246 characters and a sha of c6b13eb6046204c9, and it mentions TSM on September 10. The sixth panel has 260 characters and a sha of 1a27b01a67d941ba, and it mentions CAN on September 8. The seventh panel has 353 characters and a sha of 6c9b3b8c9ef9591b, and it mentions improved organic cash. The eighth panel has 160 characters and a sha of cb0697f278f531de, and it mentions EGTX. The ninth panel has 206 characters and a sha of 07d3a925356adce6, and it mentions EGTX conferences. The tenth panel has 99 characters and a sha of 3c0e375b916a9efe, and it mentions BFRI ITC. The eleventh panel has 341 characters and a sha of 54d249f97f35ce8c, and it mentions BFRI on September 1. The raw sha is 265e5aeb9f72b6666406610ce442f8fcd6af4b99a817aeccd9fcf5d97a2c9d13.

The fund is called Catalyst Research and it is for research only, with a size of 0. The information comes from the PRE91108 archive. On 2026-09-13 at 16:31:16, the system showed the following panels: panel 0 with 71 characters, panel 1 with information about CNXC, including a filing date of 2026-08-14 and a form called SCHEDULE 13G, panel 2 with a news headline from TBN about Tamboran delivering first gas sales, panel 3 with a link to Tamboran's corporate calendar, panel 4 with information about SRRK, including FDA approval of ISEMBYLD, panel 5 with information about NEOV, including a blog post about home battery safety, and panel 6 with information about END5 groups, including SRRK and NEOV. The system has 7 panels in total, with a raw sha of a16c77f3885481176c70f1572a81d85acf314a05449230a0557ebcdcc2bafd0e.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 13, 2026, at 16:01:10 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on August 12. A discovery was made on September 9 that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85. The GIS company had a conference on September 8, and its earnings will be released on September 23. The fund manager will review the earnings at 13 UTC and will verify the results if they are stronger or weaker than expected. The baseline for GIS is an EPS of $3.00-3.20 and organic growth of -1.5 to +0.5%. The fund manager also reviewed EAT's investor day on September 17 and will review its earnings call on October 28. The fund manager will verify the full pipelines and early news for these stocks and will not make any automatic trades. The fund's status was updated again on September 13, 2026, at 16:01:14 UTC, and it remains in research mode only, with no orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 13, 2026, at 16:01:07 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The manager also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The manager noted that the SEC filings may not be up to date with the latest news. The manager will review the following results: new morning results on September 9 at 12:30, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30 after the September 23 AMC. The manager also noted that the GRAL panel meeting on September 23 is not an approval meeting. The manager has a strong cash position and will validate and verify the results, but will not place any automatic orders.